NASDAQ · GRALHealthcareMedical Labs

GRAIL financials

$136.57+2.97%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
Revenue$147.2M$125.6M
Gross profit$71.3M$55.9M
Gross margin48.5%44.5%
Operating income-$562.2M-$2.19B
Net income-$408.4M-$2.03B
Net margin−277.5%−1613.9%
Diluted EPS$-11.11$-63.54
EBITDA-$377.8M-$610.2M
Operating cash flow-$299.0M-$577.2M
Free cash flow-$299.9M-$582.4M
Diluted shares36.8M31.9M

Balance sheet

Period endDec 31Dec 31
Cash & equivalents$249.7M$214.2M
Short-term investments$654.7M$549.2M
Total debt$0.00$0.00
Total assets$2.92B$2.98B
Total liabilities$344.2M$479.9M
Shareholders' equity$2.58B$2.50B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology